What question did this study set out to answer?

To evaluate the impact of CNS disease status on survival outcomes in pediatric acute myeloid leukemia patients.

December 8, 2025Blood

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

View Full Paper

Ask AI

Bookmark

Authors

Analysis shows CNS disease impacts event-free survival in pediatric AML, suggesting intrathecal therapy and HSCT offer protective effects.

To evaluate the impact of CNS disease status on survival outcomes in pediatric acute myeloid leukemia patients.
Patients were categorized based on CNS status from diagnostic lumbar puncture (CNS1, CNS2, CNS3).
Study compared outcomes from trial AAML1831 with historical data from AAML0531/1031.
Interventions included intrathecal chemotherapy and hematopoietic stem cell transplant for high-risk patients.
18% of patients on AAML1831 had CNS disease at diagnosis, compared to 31% on previous trials.
CNS1, CNS2, and CNS3 had 2-year event-free survival rates of 60.4%, 69.5%, and 45.6% respectively.
HSCT showed a significant protective effect against CNS relapse, with a cumulative incidence of 1% compared to 11.8% for those receiving chemo alone.

Pollard et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis shows CNS disease impacts event-free survival in pediatric AML, suggesting intrathecal therapy and HSCT offer protective effects.